Literature DB >> 19724774

General medical with depression drugs associated.

Donald Rogers1, Ronald Pies.   

Abstract

Drug-induced depression has been the focus of intense scrutiny by the US Food and Drug Administration and has serious clinical and medicolegal implications. "Gold standard" studies of drug-induced depression-involving randomized, placebo-controlled design and direct assessment of depressive symptoms-are lacking. Based on the available literature, our review suggests that only a few types of drugs are strongly linked with induction of depression. However, the potential for idiosyncratic reactions-not necessarily detected in large-scale studies-suggests that particular caution and careful monitoring are warranted with several types of drugs, including isotretinoin, rimonabant, and alpha interferons.

Entities:  

Keywords:  depressogenic; depressogenic drugs; drug-induced depression; iatrogenic depression; secondary depression

Year:  2008        PMID: 19724774      PMCID: PMC2729620     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  78 in total

1.  Captopril treatment of major depression with serial measurements of blood cortisol concentrations.

Authors:  L Germain; G Chouinard
Journal:  Biol Psychiatry       Date:  1989-02-15       Impact factor: 13.382

2.  Exacerbation of recurrent depression as a result of treatment with varenicline.

Authors:  Michael K Popkin
Journal:  Am J Psychiatry       Date:  2008-06       Impact factor: 18.112

3.  Propranolol-induced depression.

Authors:  J D Fitzgerald
Journal:  Br Med J       Date:  1967-05-06

4.  Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial.

Authors:  S B Patten; L M Metz
Journal:  Mult Scler       Date:  2001-08       Impact factor: 6.312

5.  Alprazolam, diazepam, yohimbine, clonidine: in vivo CA1 hippocampal norepinephrine and serotonin release profiles under chloral hydrate anesthesia.

Authors:  P A Broderick
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1997-10       Impact factor: 5.067

6.  Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

7.  Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial.

Authors:  Scott B Patten; Luanne M Metz
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

8.  Depression associated with nifedipine-induced calcium channel blockade.

Authors:  F J Hullett; S G Potkin; A B Levy; R Ciasca
Journal:  Am J Psychiatry       Date:  1988-10       Impact factor: 18.112

9.  A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

Authors:  Shih-Tzu Tsai; Hong-Jun Cho; Huey-Shinn Cheng; Cheol-Hwan Kim; Kuang-Chieh Hsueh; Clare B Billing; Kathryn E Williams
Journal:  Clin Ther       Date:  2007-06       Impact factor: 3.393

10.  A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.

Authors: 
Journal:  JAMA       Date:  1982-03-26       Impact factor: 56.272

View more
  12 in total

1.  Depression in the Primary Care Setting. Reply.

Authors:  Lawrence T Park; Carlos A Zarate
Journal:  N Engl J Med       Date:  2019-06-06       Impact factor: 91.245

2.  Major depression in primary care: making the diagnosis.

Authors:  Chung Wai Mark Ng; Choon How How; Yin Ping Ng
Journal:  Singapore Med J       Date:  2016-11       Impact factor: 1.858

Review 3.  The bidirectional relation between psychiatric disorders with selected cardiovascular and endocrinal diseases: an Egyptian perspective.

Authors:  Tarek Okasha; Ash-Shayma Radwan
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

Review 4.  Depression in the Primary Care Setting.

Authors:  Lawrence T Park; Carlos A Zarate
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

5.  Late Life Depression: The Essentials and the Essential Distinctions.

Authors:  Sehba Husain-Krautter; James M Ellison
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-07-09

6.  Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia.

Authors:  Yang Gao; Rónán O'Caoimh; Liam Healy; David M Kerins; Joseph Eustace; Gordon Guyatt; David Sammon; D William Molloy
Journal:  BMJ Open       Date:  2013-07-25       Impact factor: 2.692

Review 7.  Is Mania the Hypertension of the Mood? Discussion of A Hypothesis.

Authors:  Zoltán Rihmer; Xénia Gonda; Péter Döme
Journal:  Curr Neuropharmacol       Date:  2017-04       Impact factor: 7.363

8.  Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms.

Authors:  Dorothy Keine; Mark Zelek; John Q Walker; Marwan N Sabbagh
Journal:  Neurol Ther       Date:  2019-03-21

Review 9.  Psychiatric and Developmental Effects of Isotretinoin (Retinoid) Treatment for Acne Vulgaris.

Authors:  Alessandra Suuberg
Journal:  Curr Ther Res Clin Exp       Date:  2019-02-10

10.  Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study.

Authors:  Carlotta Lunghi; Ippazio Cosimo Antonazzo; Sofia Burato; Emanuel Raschi; Violetta Zoffoli; Emanuele Forcesi; Elisa Sangiorgi; Marco Menchetti; Pasquale Roberge; Elisabetta Poluzzi
Journal:  Neuropsychiatr Dis Treat       Date:  2020-05-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.